Supplemental Data
Files in this Data Supplement:
- Supplemental Data -
Supplemental Figure 1 - Reversible inhibitory effect of omeprazole on CYP2C19-catalyzed (S)-mephenytoin metabolism and CYP3A4-catalyzed midazolam metabolism in HLMs
Supplemental Figure S2 - Reversible inhibitory effect of omeprazole metabolites on CYP2C19-catalyzed (S)-mephenytoin metabolism and CYP3A4-catalyzed midazolam metabolism in HLMs
Supplemental Figure S3 - IC50 shifts of 5'-hydroxyomeprazole and carboxyomeprazole on CYP2C19-catalyzed (S)-mephenytoin metabolism...
Supplemental Figure S4 - Contribution of omeprazole and its metabolites to CYP2C19 and CYP3A4 DDI risk assessment using total Cmax
Supplemental Table 1 - IC50 shifts of omeprazole and its metabolites on CYP2C19-catalyzed (S)-mephenytoin metabolism and CYP3A4-catalyzed midazolam metabolism in the presence or absence of NADPH in pooled HLMs